ImmuPharma PLC (IMM) - Total Liabilities

Latest as of June 2025: GBX1.24 Million GBX ≈ $151.37 USD

Based on the latest financial reports, ImmuPharma PLC (IMM) has total liabilities worth GBX1.24 Million GBX (≈ $151.37 USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore ImmuPharma PLC long-term investment intensity to see how much of total assets are deployed in long-term investments.

ImmuPharma PLC - Total Liabilities Trend (2004–2024)

This chart illustrates how ImmuPharma PLC's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see IMM total asset value.

ImmuPharma PLC Competitors by Total Liabilities

The table below lists competitors of ImmuPharma PLC ranked by their total liabilities.

Company	Country	Total Liabilities
Rajvir Industries Limited NSE:RAJVIR	India	Rs1.13 Billion
Capital Metals PLC LSE:CMET	UK	GBX918.89K
Ellwee AB ST:ELLWEE	Sweden	Skr14.87 Million
GO METALS CORP. F:47GA	Germany	€75.37K
VOLTAGE METALS CORP. F:8L10	Germany	€1.66 Million
Chimeric Therapeutics Ltd AU:CHM	Australia	AU$8.96 Million
EV Digital Invest AG F:ENGL	Germany	€1.32 Million

Liability Composition Analysis (2004–2024)

This chart breaks down ImmuPharma PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See IMM net asset quality score to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.21	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	3.69	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.79	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how ImmuPharma PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for ImmuPharma PLC (2004–2024)

The table below shows the annual total liabilities of ImmuPharma PLC from 2004 to 2024.

Year	Total Liabilities	Change
2024-12-31	GBX1.52 Million ≈ $184.92	-8.72%
2023-12-31	GBX1.67 Million ≈ $202.60	+14.73%
2022-12-31	GBX1.45 Million ≈ $176.58	-8.39%
2021-12-31	GBX1.58 Million ≈ $192.76	+25.65%
2020-12-31	GBX1.26 Million ≈ $153.41	+137.07%
2019-12-31	GBX531.87K ≈ $64.71	-48.60%
2018-12-31	GBX1.03 Million ≈ $125.90	-28.28%
2017-12-31	GBX1.44 Million ≈ $175.54	+23.97%
2016-12-31	GBX1.16 Million ≈ $141.60	-23.57%
2015-12-31	GBX1.52 Million ≈ $185.26	+11.39%
2014-12-31	GBX1.37 Million ≈ $166.32	-24.12%
2013-12-31	GBX1.80 Million ≈ $219.19	-13.87%
2012-12-31	GBX2.09 Million ≈ $254.48	+17.97%
2011-12-31	GBX1.77 Million ≈ $215.72	+12.07%
2010-12-31	GBX1.58 Million ≈ $192.48	-75.88%
2009-12-31	GBX6.56 Million ≈ $798.16	+203.42%
2008-12-31	GBX2.16 Million ≈ $263.05	+105.90%
2007-12-31	GBX1.05 Million ≈ $127.75	-27.03%
2006-12-31	GBX1.44 Million ≈ $175.08	+28.14%
2006-03-31	GBX1.12 Million ≈ $136.64	+7921.43%
2005-03-31	GBX14.00K ≈ $1.70	+600.00%
2004-03-31	GBX2.00K ≈ $0.24	--

About ImmuPharma PLC

LSE:IMM UK Biotechnology

Market Cap

$223.87K

GBX1.84 Billion GBX

Market Cap Rank

#31314 Global

#1021 in UK

Share Price

GBX3.66

Change (1 day)

-3.81%

52-Week Range

GBX3.21 - GBX13.00

All Time High

GBX190.00